{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:24:27Z","timestamp":1788175467650,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["NCT01513174\/ GECP-GOAL"],"award-info":[{"award-number":["NCT01513174\/ GECP-GOAL"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.lungcan.2020.09.018","type":"journal-article","created":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T10:52:56Z","timestamp":1601722376000},"page":"62-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)"],"prefix":"10.1016","volume":"150","author":[{"given":"Rosario","family":"Garcia-Campelo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Arrieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartomeu","family":"Massuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delvys","family":"Rodriguez-Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Laura Ortega","family":"Granados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Majem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Lianes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Bosch-Barrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Insa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"D\u00f3mine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noem\u00ed","family":"Reguart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Guirado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Sala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"V\u00e1zquez-Estevez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyes Bernab\u00e9","family":"Caro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Drozdowskyj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Verd\u00fa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niki","family":"Karachaliou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel","family":"Molina-Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Rosell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"69","key":"10.1016\/j.lungcan.2020.09.018_bib0005","first-page":"7","article-title":"Cancer statistics, 2019","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lungcan.2020.09.018_bib0010","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.03022","article-title":"Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO and OH (CCO) joint guideline update","author":"Hanna","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2020.09.018_bib0015","first-page":"S23","volume":"2018","author":"Karachaliou","year":"2018"},{"key":"10.1016\/j.lungcan.2020.09.018_bib0020","first-page":"109","article-title":"Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survival","author":"Lee","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.lungcan.2020.09.018_bib0025","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-Mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2020.09.018_bib0030","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2020.09.018_bib0035","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2020.09.018_bib0040","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2020.09.018_bib0045","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/JTO.0b013e31827ecf83","article-title":"Detection of impaired homologous recombination repair in NSCLC cells and tissues","volume":"8","author":"Birkelbach","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.09.018_bib0050","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz192","article-title":"A decade of clinical development of PARP inhibitors in perspective","author":"Mateo","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2020.09.018_bib0055","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.lungcan.2020.09.018_bib0060","doi-asserted-by":"crossref","first-page":"6254","DOI":"10.1158\/0008-5472.CAN-13-0044","article-title":"EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity","volume":"73","author":"Pfaffle","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2020.09.018_bib0065","doi-asserted-by":"crossref","first-page":"11597","DOI":"10.1158\/0008-5472.CAN-05-2119","article-title":"Hypoxia-induced down-regulation of BRCA1 expression by E2Fs","volume":"65","author":"Bindra","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2020.09.018_bib0070","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1073\/pnas.0904783107","article-title":"Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130","volume":"107","author":"Hegan","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lungcan.2020.09.018_bib0075","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1158\/1078-0432.CCR-10-2158","article-title":"Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations","volume":"17","author":"Rosell","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2020.09.018_bib0080","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.8079","article-title":"Phase IB study to evaluate efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients (P) with epidermal growth factor receptor (EGFR) mutation positive advanced non-small cell lung cancer (NSCLC)","volume":"32","author":"Campelo","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2020.09.018_bib0085","volume":"36","author":"Campelo","year":"2018"},{"key":"10.1016\/j.lungcan.2020.09.018_bib0090","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2213-2600(17)30129-7","article-title":"Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial","volume":"5","author":"Rosell","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.lungcan.2020.09.018_bib0095","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2020.09.018_bib0100","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/JTO.0b013e31827db621","article-title":"BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations","volume":"8","author":"Karachaliou","year":"2013","journal-title":"J. Thorac. Oncol."},{"issue":"237\u2013249","key":"10.1016\/j.lungcan.2020.09.018_bib0105","first-page":"e236","article-title":"LMO2 confers synthetic lethality to PARP inhibition in DLBCL","volume":"36","author":"Parvin","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lungcan.2020.09.018_bib0110","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1158\/1078-0432.CCR-13-2391","article-title":"Non-disruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer","volume":"17","author":"Molina-Vila","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2020.09.018_bib0115","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1158\/1078-0432.CCR-16-0966","article-title":"Impact of TP53 mutations on outcome in EGFR-mutated patients treated with first-line tyrosine kinase inhibitors","volume":"23","author":"Canale","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2020.09.018_bib0120","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.molcel.2007.11.015","article-title":"The DNA damage response: ten years after","volume":"28","author":"Harper","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.lungcan.2020.09.018_bib0125","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/ng.3990","article-title":"Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers","volume":"49","author":"Blakely","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.lungcan.2020.09.018_bib0130","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S2213-2600(18)30264-9","article-title":"Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicenter clinical trial","volume":"6","author":"Wang","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.lungcan.2020.09.018_bib0135","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jtho.2018.10.150","article-title":"Concurrent genetic alterations predict the progression to target therapy in EGFR-mutated advanced NSCLC","volume":"14","author":"Kim","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.09.018_bib0140","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ebiom.2019.03.023","article-title":"Concurrent driver gene mutations as negative predictive factors in epidermal growth factor receptor-positive non-small cell lung cancer","volume":"42","author":"Chen","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.lungcan.2020.09.018_bib0145","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","author":"De Bono","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2020.09.018_bib0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2018.07.099","article-title":"ARID1A gene driver mutations in lung adenocarcinomas","volume":"13","author":"Karachaliou","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.09.018_bib0155","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2020.09.018_bib0160","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1158\/1078-0432.CCR-19-3563","article-title":"Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-Mutant lung cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2020.09.018_bib0165","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s42255-019-0052-9","article-title":"miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinoma","volume":"1","author":"Zhang","year":"2019","journal-title":"Nat Metab"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220306279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220306279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:06:00Z","timestamp":1777518360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500220306279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":33,"alternative-id":["S0169500220306279"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.09.018","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.09.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}